Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

Scientists Win $1.5 Million Grant to Develop New Cancer Drugs

By Drug Discovery Trends Editor | March 23, 2015

Derek Duckett is associate professor of molecular therapeutics at The Scripps Research Institute’s Florida campus.Scientists from the Florida campus of The Scripps Research Institute (TSRI) have been awarded a $1.5 million grant from the National Institutes of Health (NIH) to develop drug candidates that could treat cancer and neurodegenerative disease.
 
Derek Duckett, a TSRI associate professor of molecular therapeutics, is the co-principal investigator for the three-year study, along with John Cleveland of the Moffitt Cancer Center in Tampa, Florida. Duckett, Cleveland and their teams will look for compounds that affect a key enzyme involved in the degradation and ultimate recycling of damaged cellular material.
 
This process, called “autophagy,” is an ancient, cannibalistic (literally “self-eating”) pathway that acts as the main recycling center of all cells. In autophagy, bulk cytoplasmic material and aged or damaged organelles are recycled via the lysosome to recoup essential building blocks and adenosine triphosphate (ATP) as a survival strategy during times of stress or nutrient limitation. Autophagy is an important cell survival pathway, and any defects in its regulation can lead to a variety of disorders, including neurodegenerative disorders, liver disease and cancer.
 
The study is focused on targeting a particular enzyme, UNC-51-like kinase-1 (Ulk1), a critical on-off switch that regulates this pathway.
 
“Using these funds, we will identify new inhibitors of Ulk1,” Duckett said. “Developing selective molecular probes that function as Ulk1-specific inhibitors would improve our understanding of the autophagy pathway, its relationship to cancer and its utility as a target that could augment conventional or targeted anti-cancer treatments.”
 
Duckett and his colleagues plan to use the high-throughput screening facilities at Scripps Florida and the Scripps Drug Discovery Library and its 650,000-plus library of small-molecule compounds.
 
The number of the new grant from the NIH National Institute of General Medical Sciences is 1R01GM113972.
 
Source: Scripps Research Institute

Filed Under: Drug Discovery

 

Related Articles Read More >

Zoliflodacin wins FDA nod for treatment of gonorrhea
FDA approved ENFLONSIA for the prevention of RSV in Infants
First clinical study results of Dupixent for atopic dermatitis in patients with darker skin tones 
Labcorp widens precision oncology toolkit, aims to speed drug-trial enrollment
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE